360 related articles for article (PubMed ID: 33615743)
21. Lipid nanoparticles for siRNA delivery in cancer treatment.
El Moukhtari SH; Garbayo E; Amundarain A; Pascual-Gil S; Carrasco-León A; Prosper F; Agirre X; Blanco-Prieto MJ
J Control Release; 2023 Sep; 361():130-146. PubMed ID: 37532145
[TBL] [Abstract][Full Text] [Related]
22. TME-Responsive Multistage Nanoplatform for siRNA Delivery and Effective Cancer Therapy.
Cao S; Lin C; Li X; Liang Y; Saw PE
Int J Nanomedicine; 2021; 16():5909-5921. PubMed ID: 34475756
[TBL] [Abstract][Full Text] [Related]
23. Interaction of cholesterol-conjugated ionizable amino lipids with biomembranes: lipid polymorphism, structure-activity relationship, and implications for siRNA delivery.
Zhang J; Fan H; Levorse DA; Crocker LS
Langmuir; 2011 Aug; 27(15):9473-83. PubMed ID: 21648950
[TBL] [Abstract][Full Text] [Related]
24. Lipid nanoparticles for short interfering RNA delivery.
Leung AK; Tam YY; Cullis PR
Adv Genet; 2014; 88():71-110. PubMed ID: 25409604
[TBL] [Abstract][Full Text] [Related]
25. Synergistic silencing: combinations of lipid-like materials for efficacious siRNA delivery.
Whitehead KA; Sahay G; Li GZ; Love KT; Alabi CA; Ma M; Zurenko C; Querbes W; Langer RS; Anderson DG
Mol Ther; 2011 Sep; 19(9):1688-94. PubMed ID: 21750531
[TBL] [Abstract][Full Text] [Related]
26. Understanding structure-activity relationships of pH-sensitive cationic lipids facilitates the rational identification of promising lipid nanoparticles for delivering siRNAs in vivo.
Sato Y; Hashiba K; Sasaki K; Maeki M; Tokeshi M; Harashima H
J Control Release; 2019 Feb; 295():140-152. PubMed ID: 30610950
[TBL] [Abstract][Full Text] [Related]
27. Charge-reversible lipid derivative: A novel type of pH-responsive lipid for nanoparticle-mediated siRNA delivery.
Hirai Y; Saeki R; Song F; Koide H; Fukata N; Tomita K; Maeda N; Oku N; Asai T
Int J Pharm; 2020 Jul; 585():119479. PubMed ID: 32473372
[TBL] [Abstract][Full Text] [Related]
28. Innovative lipoplexes formulations with enhanced siRNA efficacy for cancer treatment: Where are we now?
Berger M; Lechanteur A; Evrard B; Piel G
Int J Pharm; 2021 Aug; 605():120851. PubMed ID: 34217823
[TBL] [Abstract][Full Text] [Related]
29. Next-Generation Lipids in RNA Interference Therapeutics.
Rietwyk S; Peer D
ACS Nano; 2017 Aug; 11(8):7572-7586. PubMed ID: 28727419
[TBL] [Abstract][Full Text] [Related]
30. Surface Design Options in Polymer- and Lipid-Based siRNA Nanoparticles Using Antibodies.
Gabel M; Knauss A; Fischer D; Neurath MF; Weigmann B
Int J Mol Sci; 2022 Nov; 23(22):. PubMed ID: 36430411
[TBL] [Abstract][Full Text] [Related]
31. Advances with Lipid-Based Nanosystems for siRNA Delivery to Breast Cancers.
Subhan MA; Filipczak N; Torchilin VP
Pharmaceuticals (Basel); 2023 Jul; 16(7):. PubMed ID: 37513882
[TBL] [Abstract][Full Text] [Related]
32. Recent Advances in siRNA Delivery Systems for Prostate Cancer Therapy.
Aghamiri S; Raee P; Shahmohamadnejad S; Shabani S; Ghorbani J; Sameni M; Ebrahimi MT
Curr Pharm Biotechnol; 2022; 23(4):579-593. PubMed ID: 34132181
[TBL] [Abstract][Full Text] [Related]
33. Biodegradable lipid nanoparticles induce a prolonged RNA interference-mediated protein knockdown and show rapid hepatic clearance in mice and nonhuman primates.
Suzuki Y; Hyodo K; Suzuki T; Tanaka Y; Kikuchi H; Ishihara H
Int J Pharm; 2017 Mar; 519(1-2):34-43. PubMed ID: 28089936
[TBL] [Abstract][Full Text] [Related]
34. Single-step assembly of cationic lipid-polymer hybrid nanoparticles for systemic delivery of siRNA.
Yang XZ; Dou S; Wang YC; Long HY; Xiong MH; Mao CQ; Yao YD; Wang J
ACS Nano; 2012 Jun; 6(6):4955-65. PubMed ID: 22646867
[TBL] [Abstract][Full Text] [Related]
35. Advances in RNAi therapeutic delivery to leukocytes using lipid nanoparticles.
Ramishetti S; Landesman-Milo D; Peer D
J Drug Target; 2016 Nov; 24(9):780-786. PubMed ID: 27030014
[TBL] [Abstract][Full Text] [Related]
36. The landscape of nanoparticle-based siRNA delivery and therapeutic development.
Moazzam M; Zhang M; Hussain A; Yu X; Huang J; Huang Y
Mol Ther; 2024 Feb; 32(2):284-312. PubMed ID: 38204162
[TBL] [Abstract][Full Text] [Related]
37. Recent developments in nanoparticle-based siRNA delivery for cancer therapy.
Lee JM; Yoon TJ; Cho YS
Biomed Res Int; 2013; 2013():782041. PubMed ID: 23844368
[TBL] [Abstract][Full Text] [Related]
38. Systemic delivery of siRNA with cationic lipid assisted PEG-PLA nanoparticles for cancer therapy.
Yang XZ; Dou S; Sun TM; Mao CQ; Wang HX; Wang J
J Control Release; 2011 Dec; 156(2):203-11. PubMed ID: 21839126
[TBL] [Abstract][Full Text] [Related]
39. [Development of an efficient short interference RNA (siRNA) delivery system with a new pH-sensitive cationic lipid].
Sato Y; Hatakeyama H; Hyodo M; Akita H; Harashima H
Yakugaku Zasshi; 2012; 132(12):1355-63. PubMed ID: 23208041
[TBL] [Abstract][Full Text] [Related]
40. Multifunctional peptide-lipid nanocomplexes for efficient targeted delivery of DNA and siRNA into breast cancer cells.
Wan Y; Dai W; Nevagi RJ; Toth I; Moyle PM
Acta Biomater; 2017 Sep; 59():257-268. PubMed ID: 28655658
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
